Aurinia Pharmaceuticals (AUPH) Revenue & Revenue Breakdown
Aurinia Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$158.53M
Latest Revenue (Q)
$55.03M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Aurinia Pharmaceuticals Revenue by Period
Aurinia Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $158.53M | 18.28% |
| 2022-12-31 | $134.03M | 193.89% |
| 2021-12-31 | $45.60M | -9.00% |
| 2020-12-31 | $50.12M | 15660.38% |
| 2019-12-31 | $318.00K | -31.32% |
| 2018-12-31 | $463.00K | 10.24% |
| 2017-12-31 | $420.00K | 142.77% |
| 2016-12-31 | $173.00K | -26.38% |
| 2015-12-31 | $235.00K | -15.47% |
| 2014-12-31 | $278.00K | -70.69% |
| 2013-12-31 | $948.56K | -84.60% |
| 2012-12-31 | $6.16M | 563.90% |
| 2011-12-31 | $927.52K | -72.88% |
| 2010-12-31 | $3.42M | -15.59% |
| 2009-12-31 | $4.05M | 4.52% |
| 2008-12-31 | $3.88M | 66.05% |
| 2007-12-31 | $2.33M | -33.72% |
| 2006-12-31 | $3.52M | 199.06% |
| 2005-12-31 | $1.18M | -7.51% |
| 2004-12-31 | $1.27M | -83.38% |
| 2003-12-31 | $7.66M | -35.71% |
| 2002-12-31 | $11.92M | 124.97% |
| 2001-12-31 | $5.30M | 486.77% |
| 2000-11-30 | $902.77K | -33.53% |
| 1999-11-30 | $1.36M | 73.85% |
| 1998-11-30 | $781.25K | - |
Aurinia Pharmaceuticals generated $158.53M in revenue during NA 2023, up 18.28% compared to the previous quarter, and up 34240.39% compared to the same period a year ago.
Aurinia Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $55.03M | 9.39% |
| 2024-03-31 | $50.30M | 11.55% |
| 2023-12-31 | $45.09M | -17.28% |
| 2023-09-30 | $54.52M | 31.38% |
| 2023-06-30 | $41.49M | 20.59% |
| 2023-03-31 | $34.41M | 21.01% |
| 2022-12-31 | $28.43M | -49.02% |
| 2022-09-30 | $55.78M | 97.86% |
| 2022-06-30 | $28.19M | 30.36% |
| 2022-03-31 | $21.63M | -7.60% |
| 2021-12-31 | $23.40M | 59.57% |
| 2021-09-30 | $14.67M | 121.56% |
| 2021-06-30 | $6.62M | 624.29% |
| 2021-03-31 | $914.00K | -98.17% |
| 2020-12-31 | $50.03M | 172417.24% |
| 2020-09-30 | $29.00K | - |
| 2020-06-30 | $29.00K | -3.33% |
| 2020-03-31 | $30.00K | 3.45% |
| 2019-12-31 | $29.00K | -87.39% |
| 2019-09-30 | $230.00K | 693.10% |
| 2019-06-30 | $29.00K | -3.33% |
| 2019-03-31 | $30.00K | 3.45% |
| 2018-12-31 | $29.00K | -92.27% |
| 2018-09-30 | $375.00K | 1193.10% |
| 2018-06-30 | $29.00K | -3.33% |
| 2018-03-31 | $30.00K | -3.23% |
| 2017-12-31 | $31.00K | 6.90% |
| 2017-09-30 | $29.00K | -91.19% |
| 2017-06-30 | $329.00K | 961.29% |
| 2017-03-31 | $31.00K | 3.33% |
| 2016-12-31 | $30.00K | -3.23% |
| 2016-09-30 | $31.00K | -43.64% |
| 2016-06-30 | $55.00K | -3.51% |
| 2016-03-31 | $57.00K | - |
| 2015-12-31 | $57.00K | - |
| 2015-09-30 | $57.00K | -3.39% |
| 2015-06-30 | $59.00K | -4.84% |
| 2015-03-31 | $62.00K | -8.82% |
| 2014-12-31 | $68.00K | -5.56% |
| 2014-09-30 | $72.00K | 1.41% |
| 2014-06-30 | $71.00K | 5.97% |
| 2014-03-31 | $67.00K | -90.33% |
| 2013-12-31 | $692.64K | 721.28% |
| 2013-09-30 | $84.34K | 2.00% |
| 2013-06-30 | $82.69K | -5.47% |
| 2013-03-31 | $87.47K | 1.47% |
| 2012-12-31 | $86.21K | -1.34% |
| 2012-09-30 | $87.38K | -1.26% |
| 2012-06-30 | $88.49K | -98.48% |
| 2012-03-31 | $5.81M | 4745.76% |
| 2011-12-31 | $119.97K | -77.57% |
| 2011-09-30 | $534.84K | 250.00% |
| 2011-06-30 | $152.81K | 10.83% |
| 2011-03-31 | $137.87K | -53.70% |
| 2010-12-31 | $297.75K | 12.95% |
| 2010-09-30 | $263.62K | -81.35% |
| 2010-06-30 | $1.41M | -2.37% |
| 2010-03-31 | $1.45M | -12.58% |
| 2009-12-31 | $1.66M | 72.55% |
| 2009-09-30 | $959.87K | 55.20% |
| 2009-06-30 | $618.46K | -4.42% |
| 2009-03-31 | $647.03K | 592.40% |
| 2008-12-31 | $93.45K | -96.54% |
| 2008-09-30 | $2.70M | 386.86% |
| 2008-06-30 | $555.12K | -1.32% |
| 2008-03-31 | $562.52K | -8.72% |
| 2007-12-31 | $616.27K | - |
Aurinia Pharmaceuticals generated $55.03M in revenue during Q2 2024, up 9.39% compared to the previous quarter, and up 159.92% compared to the same period a year ago.
Aurinia Pharmaceuticals Revenue Breakdown
Aurinia Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Product | $158.53M | $103.47M | $45.49M | - |
| License, Collaboration and Royalty Revenue | $16.98M | - | - | - |
| License | - | $30.56M | $117.00K | $50.12M |
Aurinia Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (90.33%), and License, Collaboration and Royalty Revenue (9.67%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $55.03M | $48.07M | $42.31M | $40.78M | $41.10M | $34.34M | $28.33M | $25.50M | $28.15M | $21.49M | $23.38M | $14.64M | $6.59M | $30.00K |
| License, Royalty and Collaboration Revenue | $2.16M | $2.23M | $13.73M | $394.00K | $72.00K | - | - | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | $109.00K | $30.28M | $43.00K | $133.00K | $29.00K | $29.00K | $29.00K | $884.00K |
Aurinia Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (96.22%), and License, Royalty and Collaboration Revenue (3.78%).
Aurinia Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $157.96M | $102.46M | $45.49M | - | $200.00K |
| JAPAN | $17.55M | $31.48M | - | $50.00M | - |
| Other Country | - | $89.00K | $117.00K | - | - |
| CHINA | - | - | - | $118.00K | $118.00K |
Aurinia Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (90.00%), and JAPAN (10.00%).
Aurinia Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EXEL | Exelixis | $1.83B | $478.06M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| AUPH | Aurinia Pharmaceuticals | $158.53M | $55.03M |
| MCRB | Seres Therapeutics | $126.33M | - |
| BTAI | BioXcel Therapeutics | $1.38M | $1.10M |
| VKTX | Viking Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
AUPH Revenue FAQ
What is Aurinia Pharmaceuticals’s yearly revenue?
Aurinia Pharmaceuticals's yearly revenue for 2023 was $158.53M, representing an increase of 18.28% compared to 2022. The company's yearly revenue for 2022 was $134.03M, representing an increase of 193.89% compared to 2021. AUPH's yearly revenue for 2021 was $45.6M, representing a decrease of -9.00% compared to 2020.
What is Aurinia Pharmaceuticals’s quarterly revenue?
Aurinia Pharmaceuticals's quarterly revenue for Q2 2024 was $55.03M, a 9.39% increase from the previous quarter (Q1 2024), and a 32.62% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50.3M, a 11.55% increase from the previous quarter (Q4 2023), and a 46.19% increase year-over-year (Q1 2023). AUPH's quarterly revenue for Q4 2023 was $45.1M, a -17.28% decrease from the previous quarter (Q3 2023), and a 58.59% increase year-over-year (Q4 2022).
What is Aurinia Pharmaceuticals’s revenue growth rate?
Aurinia Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 247.62%, and for the last 5 years (2019-2023) was 49753.14%.
What are Aurinia Pharmaceuticals’s revenue streams?
Aurinia Pharmaceuticals's revenue streams in c 23 are Product, and License, Collaboration and Royalty Revenue. Product generated $158.53M in revenue, accounting 90.33% of the company's total revenue, up 53.22% year-over-year. License, Collaboration and Royalty Revenue generated $16.98M in revenue, accounting 9.67% of the company's total revenue
What is Aurinia Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Aurinia Pharmaceuticals was Product. This segment made a revenue of $158.53M, representing 90.33% of the company's total revenue.